Skip to main content

Neoclarityn Disease Interactions

There are 2 disease interactions with Neoclarityn (desloratadine).

Moderate

Desloratadine (applies to Neoclarityn) asthma

Moderate Potential Hazard, Moderate plausibility.

Desloratadine products contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Caution is advised when using these products in people with asthma.

References

  1. (2002) "Product Information. Clarinex (desloratadine)." Schering Corporation
Moderate

Desloratadine (applies to Neoclarityn) renal/hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Dosing adjustment of desloratadine is recommended for patients with renal or hepatic impairment. Dosing recommendations for children with liver or renal impairment cannot be made due to lack of data.

References

  1. (2002) "Product Information. Clarinex (desloratadine)." Schering Corporation

Neoclarityn drug interactions

There are 20 drug interactions with Neoclarityn (desloratadine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.